Which Patients are most likely to be receptive to RDN?
Hypertension and Renal Denervation. This resource helps non-invasive cardiologists, hypertension specialists, general practitioners, and nephrologists understand the benefits of Renal Denervation...
Hypertension and Renal Denervation. This resource helps non-invasive cardiologists, hypertension specialists, general practitioners, and nephrologists understand the benefits of Renal Denervation as an adjunctive therapy for treating Hypertension.
It answers frequently asked questions with the latest expert opinions, guideline summaries, and essential information for practical adoption in managing uncontrolled and resistant Hypertension.
Learn about patient selection, key evidence for safety, effectiveness, durability, and integrating Renal Denervation into your practice.
Supported by an educational grant from Medtronic.
Speakers
Melvin Lobo
Speaker
Professor Melvin Lobo is a Consultant Cardiovascular Physician based in St Bartholomew’s Heart... Professor Melvin Lobo is a Consultant Cardiovascular Physician based in St Bartholomew’s Heart Hospital and the William Harvey Research Institute. He has a specialist interest in blood pressure disorders of all types, autonomic control of the circulation and also resistant hypertension and device-based therapies thereof. He is an accredited Clinical Hypertension Specialist of the European Society of Hypertension (ESH) and British Hypertension Society. Professor Lobo is Director of the Bart's Blood Pressure Clinic which is a Hypertension Centre of Excellence and receives referrals of complex hypertensive patients on a national/international basis and has contributed to several landmark studies in hypertension. His research work has been featured on television and in the national press on numerous occasions (see website for details). In addition to hypertension, he is also an acknowledged expert in the management of low blood pressure (hypotension) and BP variability disorders and PoTS (postural tachycardia syndrome) and sees patients on a national basis with these issues in the Barts BP Clinic and on an international basis in his private practice. He has the largest cohort of medication intolerant patients nationally and has evolved, published and lectured on special strategies with liquid and patch formulations of antihypertensives to get around intolerances to tablets. He is recognised globally as a key opinion leader in his field and this is reflected in key roles in multicentre clinical trials, invited lectures at major conferences and also as an editor/reviewer of numerous journals including JACC and Lancet. More recently he has authored national and co-authored international guidelines for device therapy of hypertension which were published in the prestigious European Heart Journal. He organises and co-chairs the UK Annual Symposia on Renal Denervation with a distinguished panel of international authorities in hypertension medicine. He is a specialist adviser to NICE and the European Society of Hypertension on interventional therapies in hypertension and a member of the Council on Hypertension of the European Society of Cardiology.